Atara Biotherapeutics (NASDAQ:ATRA) Posts Earnings Results, Beats Expectations By $0.51 EPS

Atara Biotherapeutics (NASDAQ:ATRA) issued its earnings results on Wednesday. The biotechnology company reported ($0.32) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.83) by $0.51, Zacks reports. The firm had revenue of $3.45 million during the quarter, compared to analysts’ expectations of $2.74 million. Atara Biotherapeutics had a net margin of 15.40% and a negative return on equity of 37.46%.

Atara Biotherapeutics Price Performance

Shares of NASDAQ:ATRA opened at $13.39 on Friday. The business’s 50 day moving average price is $13.63 and its 200-day moving average price is $10.89. Atara Biotherapeutics has a 1 year low of $5.01 and a 1 year high of $18.70. The firm has a market capitalization of $94.00 million, a price-to-earnings ratio of 6.14 and a beta of 0.26.

Analyst Ratings Changes

Separately, Weiss Ratings lowered Atara Biotherapeutics from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Friday, November 7th. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $21.00.

Institutional Trading of Atara Biotherapeutics

Several institutional investors have recently modified their holdings of the stock. Raymond James Financial Inc. purchased a new stake in shares of Atara Biotherapeutics during the second quarter worth about $31,000. Marshall Wace LLP purchased a new position in Atara Biotherapeutics in the 2nd quarter valued at about $327,000. Geode Capital Management LLC boosted its holdings in Atara Biotherapeutics by 2.5% in the 2nd quarter. Geode Capital Management LLC now owns 60,136 shares of the biotechnology company’s stock worth $464,000 after buying an additional 1,457 shares during the last quarter. Mackenzie Financial Corp increased its stake in Atara Biotherapeutics by 183.5% during the 3rd quarter. Mackenzie Financial Corp now owns 63,816 shares of the biotechnology company’s stock worth $914,000 after buying an additional 41,302 shares in the last quarter. Finally, Vanguard Group Inc. increased its stake in Atara Biotherapeutics by 6.6% during the 3rd quarter. Vanguard Group Inc. now owns 203,438 shares of the biotechnology company’s stock worth $2,915,000 after buying an additional 12,677 shares in the last quarter. Institutional investors and hedge funds own 70.90% of the company’s stock.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.